Navigation Links
PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
Date:7/16/2008

- Expanded Collaboration Supports Pivotal Phase 2b Clinical Trials of First Potential Therapy to Address an Underlying Cause of Cystic Fibrosis -

SOUTH PLAINFIELD, N.J. and BETHESDA, Md., July 16 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, today announced the expansion of an existing collaboration to support development of PTC124, the PTC's new investigational oral drug for the treatment of cystic fibrosis (CF) caused by nonsense mutations. PTC will receive up to $25 million from CFFT in support of key Phase 2b clinical trials for PTC124 in CF.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

"We are pleased to expand our collaboration with PTC Therapeutics on the development of the therapy PTC124," said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. "The encouraging data from the Phase 2a studies indicate that PTC may become a very important drug for the treatment of CF in the 10 percent of patients who carry nonsense mutations. These exciting results lead us to believe PTC124 has the potential to be one of the first oral drugs on the market to address the basic defect in cystic fibrosis."

"We are honored both to receive this award and to continue our productive collaboration with the Foundation," stated Stuart W. Peltz, Ph.D., president and chief executive officer of PTC Therapeutics. "The significant progress that we have made with PTC124 is a result of our unique drug discovery approach as well as the extraordinary support that we have received from the physician, patient, advocacy and regulatory communities. We look forward to initiating registration-directed studies of PTC124 for nonsense-mutation- mediated CF within the next few months."

In June 2008, PTC announced encouraging new
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
2. Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients
3. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
4. Silence Therapeutics Announces Board Changes
5. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
6. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
7. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
8. CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
9. Pilot Therapeutics Announces Relaunch as Gene Smart(TM) Health
10. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
11. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Quest Diagnostics (NYSE: DGX ), the world,s ... its Board of Directors has elected Jeffrey M. Leiden, ... 2014. Including Dr. Leiden, the Board has 11 members. ... CEO of Vertex Pharmaceuticals.   Dr. Leiden has more ... the pharmaceutical and biotechnology industries as well as clinical ...
(Date:10/22/2014)... IRVINE, Calif. , Oct 22, 2014 ... Irvine, California , announced the receipt ... Small Business Innovation Research award (SBIR) from the National Institute of ... will fund the development of a Pan-HIV Protein Microarray ... the HIV-1 and HIV-2 subtypes and aid in the ...
(Date:10/22/2014)... , Oct. 22, 2014   Reproductive Medicine ... leader in the field of infertility, presents new ... embryonic screening. The research abstract, released during the ... Medicine (ASRM) meeting in Honolulu, Hawaii ... single gene defect (SGD) pre-implantation genetic diagnosis (PGD). ...
Breaking Medicine Technology:Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3
... The U.S. Food and Drug Administration today approved ... term, once-daily maintenance bronchodilator treatment of airflow obstruction ... including chronic bronchitis and/or emphysema. (Logo: ... a serious lung disease that makes breathing difficult. ...
... 1, 2011 Janssen Pharmaceuticals, Inc. announced today that ... XARELTO® (rivaroxaban tablets), a novel, once-daily, oral anticoagulant for ... may lead to a pulmonary embolism (PE) in people ... "The approval of once-daily XARELTO® tablets will provide a ...
Cached Medicine Technology:FDA Approves Arcapta Neohaler to Treat Chronic Obstructive Pulmonary Disease 2FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery 2FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery 3FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery 4FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery 5FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery 6
(Date:10/22/2014)... -- The United States is now mandating that ... West Africa land at one of five airports ... virus. In a statement released Tuesday, Homeland ... of air passengers from Guinea, Liberia and Sierra ... airports -- New York City,s Kennedy International Airport, ...
(Date:10/22/2014)... Angeles, California (PRWEB) October 22, 2014 Hay ... 2.0: Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) ... field of Yoga & Recovery. This book is meant ... thrive in a life of recovery. , Recovery 2.0 ... the 12 Steps; Recovery 2.0 is a guide for what ...
(Date:10/22/2014)... Cheap Hosting USA is among the most distinguished review ... that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the best cheap ... , “iPower is one of the most reliable hosting ... of useful products for new and old clients. What’s ... and a number of features which will appeal to ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Although there are only ... time for many people who have trouble finding time within their ... to exercise for long periods of time to get in shape. ... goals while on the go. , Change Up Your Commute ... to work to add some exercise into your daily routine. If ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately ... bacterial infections, microbial biofilms, and chronic wounds, announced that ... directors. , Dr. Sinskey is a ... Institute of Technology, or MIT. He has been a ... also holds positions as Co-Director of the Malaysia-MIT Biotechnology ...
Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2
... pressure are at even greater risk, study finds ... have fluctuating blood pressure in addition to high blood ... research shows. , Cerebrovascular disease, which includes stroke and ... associated with disability and a decline in memory and ...
... not be ignored , MONDAY, May 10 (HealthDay News) -- ... the most commonly prescribed drugs in the United States, but ... are showing the potential for serious side effects. , Five ... Archives of Internal Medicine explore the side effects ...
... ... with Down syndrome , ... May 10, 2010 -- One person can make a difference, one dollar at a time: ... lifelong learning center for people with Trisomy 21 (better known as Down syndrome). Launched one ...
... - The Massachusetts Eye and Ear Infirmary, Harvard Medical ... renewal from the National Institutes of Health, National Eye ... scientists to promote translational and clinical research into cures ... five-year K12 grant to Mass. Eye and Ear (representing ...
... Nurse staffing ... newly adopted U.S. Health Care Reform legislation. Current healthcare reform legislation indicates that more ... , ... (PRWEB) May 10, 2010 -- Nurse staffing agency, FlexRN, announces its plans to help agency ...
... ... On behalf of our team of Judges and Management ... & IT Architecture Excellence Award competition! These international awards along with ... on architects and organization for significant achievements in the field of ...
Cached Medicine News:Health News:Fluctuating Blood Pressure Ups Stroke Risk 2Health News:Stomach Acid Drugs Come with Dangers, Studies Show 2Health News:Stomach Acid Drugs Come with Dangers, Studies Show 3Health News:Stomach Acid Drugs Come with Dangers, Studies Show 4Health News:Charity Asks for $1 2Health News:Mass. Eye and Ear receives NEI grant renewal for 'growing' clinical/scientists 2Health News:FlexRN Nurse Staffing Agency Prepares Nurses for Demands of Latest Health Care Reform 2Health News:iCMG Architecture Awards for Truly Outstanding Enterprise and IT Excellence 2Health News:iCMG Architecture Awards for Truly Outstanding Enterprise and IT Excellence 3
...
... steel construction for lifelong quality. Sealed hydraulic ... chair movement. Soft, contoured cushions with heavy-duty ... counter-balanced slit lamp arm for easy, smooth, ... slit lamp arm for easy access to ...
Our Ophthalmic Diagnostic Sets offer everything an eye care specialist needs. Complete your set with your choice of ophthalmoscope, retinoscope, handle, and case....
3.5v Coaxial Ophthalmoscope Set with Convertible Handle and Hard Case. Our 3.5v Coaxial Ophthalmoscope Sets feature high-quality instruments, handles, and cases....
Medicine Products: